Eton Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ETON Eton Pharmaceuticals Inc
LXRX Lexicon Pharmaceuticals Inc
BVS Bioventus Inc
TDS-U Telephone and Data Systems Inc
ELEV Elevation Oncology Inc
FRZA Forza X1 Inc
SIEN Sientra Inc
PMGM Priveterra Acquisition Corp
NVFY Nova LifeStyle Inc
GGIFF Garibaldi Resources Corp
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Eton Pharmaceuticals, Inc. is a pharmaceutical company, which is developing, acquiring and commercializing products to address unmet needs in patients suffering from rare diseases. It has three commercial rare disease products, ALKINDI SPRINKLE for the treatment of adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase deficiency, and Betaine Anhydrous for the treatment of homocystinuria. It also has three additional product candidates in late-stage development. The Company is developing dehydrated alcohol injection, which has received Orphan Drug Designation for the treatment of methanol poisoning, ZENEO hydrocortisone autoinjector for the treatment of adrenal crisis, and ET-400. Its dehydrated alcohol injection product candidate is under review for the treatment of methanol poisoning. Its ZENEO hydrocortisone autoinjector product candidate is a needle-free autoinjector under development for the treatment of adrenal crisis.

Price
Delayed
$3.85
Day's Change
-0.04 (-1.03%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.93
Day's Low
3.85
Volume
(Light)

Today's volume of 4,770 shares is on pace to be much lighter than ETON's 10-day average volume of 46,800 shares.

4,770

Marathon Shareholder Action Reminder

11:33 am ET March 19, 2023 (Newsfile) Print

New York, New York--(Newsfile Corp. - March 19, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marathon Digital Holdings Inc. ("Marathon" or the "Company") (NASDAQ: MARA).

If you suffered losses exceeding $50,000 investing in Marathon stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may alsoclick here for additional information: www.faruqilaw.com/MARA.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6455/158980_fc83a44494c93844_001full.jpg



There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

On February 28, 2023, Marathon issued press release announcing "that it has cancelled its webcast and conference call for the fourth quarter and fiscal year 2022, initially scheduled for today, February 28, 2023, at 4:30 p.m. Eastern time, and will postpone the publication of its corresponding financial results." The company also disclosed that on Feb. 22, Marathon received a comment letter from the Corporation Finance Staff of the U.S. Securities and Exchange Commission relating to issues including accounting matters.

The audit committee of Marathon's board concluded that audited financial statements in its Form 10-K for 2021 and unaudited statements for interim periods in several quarterly reports should no longer be relied upon.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/158980

comtex tracking

COMTEX_427008476/2523/2023-03-19T11:33:06

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.